BNP Paribas Asset Management
RPRX icon

BNP Paribas Asset Management’s Royalty Pharma RPRX Stock Holding History

BNP Paribas Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67.6M Buy
1,203,706
+25,923
+2% +$1.35M 0.07% 271
2026
Q1 		$56.3M Sell
1,177,783
-27,826
-2% -$1.22M 0.07% 282
2025
Q4 		$46.6M Buy
1,205,609
+256,844
+27% +$9.79M 0.05% 325
2025
Q3 		$33.3M Sell
948,765
-9,324
-1% -$338K 0.09% 243
2025
Q2 		$34.5M Buy
958,089
+65,801
+7% +$2.18M 0.08% 235
2025
Q1 		$27.8M Buy
892,288
+262,348
+42% +$8.32M 0.07% 258
2024
Q4 		$16.1M Sell
629,940
-4,561
-0.7% -$121K 0.04% 384
2024
Q3 		$17.9M Buy
634,501
+234,991
+59% +$6.51M 0.04% 326
2024
Q2 		$10.5M Buy
399,510
+217,767
+120% +$6.04M 0.03% 414
2024
Q1 		$5.52M Buy
181,743
+19,642
+12% +$579K 0.01% 512
2023
Q4 		$4.55M Buy
162,101
+1,044
+0.6% +$28.7K 0.01% 536
2023
Q3 		$4.37M Buy
161,057
+19,626
+14% +$583K 0.01% 543
2023
Q2 		$4.35M Buy
141,431
+103,863
+276% +$3.52M 0.01% 547
2023
Q1 		$1.35M Sell
37,568
-2,771
-7% -$103K ﹤0.01% 726
2022
Q4 		$1.59M Buy
40,339
+15,732
+64% +$657K 0.01% 705
2022
Q3 		$989K Buy
+24,607
New +$1.05M ﹤0.01% 759

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BNP Paribas Asset Management's RPRX Position: Q2 2026 in Review

BNP Paribas Asset Management increased its Royalty Pharma (RPRX) stake by 2.2% in Q2 2026, buying an estimated $1.35M and bringing the position to 1,203,706 shares worth $67.6M. The position accounts for 0.07% of the portfolio, ranked #271.

BNP Paribas Asset Management first reported a position in RPRX in Q3 2022 and has held it in 16 quarters since. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • BNP Paribas Asset Management held 1,203,706 shares of Royalty Pharma worth $67.6M as of Q2 2026.
  • BNP Paribas Asset Management bought 25,923 Royalty Pharma shares in Q2 2026, an estimated $1.35M.
  • Royalty Pharma made up 0.07% of BNP Paribas Asset Management's portfolio in Q2 2026, its #271 holding.
  • BNP Paribas Asset Management first reported a position in Royalty Pharma in Q3 2022 and has held it in 16 quarters since.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.